ArticleBiochemia medica2025
Automated urine analyzers: a comparative study of Atellica UAS 800 and UAS 60 with risk analysis.
Article in Biochemia medica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This study compared analytical and technical performance of Atellica UAS 800 and UAS 60 and assessed potential patient risks if results were not reviewed by laboratory personnel. Materials and methods: The study included 463 urine samples collected from February to March 2024, analyzed on both analyzers within 2 hours by two laboratory operators. Results from the UAS 800, recorded after operator review, were considered as the reference and compared to UAS 60 results obtained before and after review. Data were evaluated using weighted kappa (kappa ≥ 0.6 considered acceptable). Technical comparison was based on operator assessment. For risk analysis 23 errors and four severity levels were defined. Results: After automatic image evaluation strong agreement was observed for calcium oxalate and yeasts (kappa: 0.83, 0.94), moderate agreement for red and white blood cells and epithelial cells (kappa: 0.75, 0.78, 0.75), weak agreement for bacteria, mucus and non-squamous epithelial cells (kappa: 0.57, 0.59, 0.40), and poorest agreement for hyaline and pathological casts and total crystals (kappa: 0.23, 0.07, 0.36). After review, kappa was acceptable for all parameters. Risk analysis identified 15 errors, with unrecognized total crystals and mucus being the most frequent (30.0%, 17.1%). Three errors were classified as intermediate risk (missing to report total crystal +1, mucus +1 and pathological casts ≥ +1), with none in high risk area. UAS 800 offers higher throughput and automatic sample aspiration, while UAS 60 uses manual aspiration. Conclusions: Atellica UAS 60 provides results comparable to UAS 800, quality of reported results remaining uncompromised even without operator review. It is suitable for low- to mid-volume laboratories and can serve as a backup in larger laboratories.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.